351 related articles for article (PubMed ID: 35312858)
1. One changing and challenging scenario: the treatment of cancer patients with bone metastases by bisphosphonates and denosumab, the cost-benefit evaluation of different options, and the risk of medication-related osteonecrosis of the jaw (MRONJ).
Fusco V; Campisi G; Bedogni A
Support Care Cancer; 2022 Sep; 30(9):7047-7051. PubMed ID: 35312858
[TBL] [Abstract][Full Text] [Related]
2. Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis.
Jakob T; Tesfamariam YM; Macherey S; Kuhr K; Adams A; Monsef I; Heidenreich A; Skoetz N
Cochrane Database Syst Rev; 2020 Dec; 12(12):CD013020. PubMed ID: 33270906
[TBL] [Abstract][Full Text] [Related]
3. Interventions for managing medication-related osteonecrosis of the jaw.
Beth-Tasdogan NH; Mayer B; Hussein H; Zolk O
Cochrane Database Syst Rev; 2017 Oct; 10(10):CD012432. PubMed ID: 28983908
[TBL] [Abstract][Full Text] [Related]
4. Switching from zoledronic acid to denosumab increases the risk for developing medication-related osteonecrosis of the jaw in patients with bone metastases.
Ikesue H; Doi K; Morimoto M; Hirabatake M; Muroi N; Yamamoto S; Takenobu T; Hashida T
Cancer Chemother Pharmacol; 2021 Jun; 87(6):871-877. PubMed ID: 33791853
[TBL] [Abstract][Full Text] [Related]
5. Associated characteristics and treatment outcomes of medication-related osteonecrosis of the jaw in patients receiving denosumab or zoledronic acid for bone metastases.
Ikesue H; Mouri M; Tomita H; Hirabatake M; Ikemura M; Muroi N; Yamamoto S; Takenobu T; Tomii K; Kawakita M; Katoh H; Ishikawa T; Yasui H; Hashida T
Support Care Cancer; 2021 Aug; 29(8):4763-4772. PubMed ID: 33527228
[TBL] [Abstract][Full Text] [Related]
6. [Position paper on medication-related osteonecrosis of the jaw (MRONJ)].
Svejda B; Muschitz Ch; Gruber R; Brandtner Ch; Svejda Ch; Gasser RW; Santler G; Dimai HP
Wien Med Wochenschr; 2016 Feb; 166(1-2):68-74. PubMed ID: 26847441
[TBL] [Abstract][Full Text] [Related]
7. Medication-related osteonecrosis of the jaw: Prevention, diagnosis and management in patients with cancer and bone metastases.
Otto S; Pautke C; Van den Wyngaert T; Niepel D; Schiødt M
Cancer Treat Rev; 2018 Sep; 69():177-187. PubMed ID: 30055439
[TBL] [Abstract][Full Text] [Related]
8. Denosumab, an Alternative to Bisphosphonates but also Associated with Osteonecrosis of the Jaw--What is the Risk?
Sidhu HK
Dent Update; 2015 Jun; 42(5):436-8, 440. PubMed ID: 26964445
[TBL] [Abstract][Full Text] [Related]
9. Incidence and Risk Factors of Osteonecrosis of the Jaw in Advanced Cancer Patients after Treatment with Zoledronic Acid or Denosumab: A Retrospective Cohort Study.
Kajizono M; Sada H; Sugiura Y; Soga Y; Kitamura Y; Matsuoka J; Sendo T
Biol Pharm Bull; 2015; 38(12):1850-5. PubMed ID: 26632176
[TBL] [Abstract][Full Text] [Related]
10. Risk evaluation of denosumab and zoledronic acid for medication-related osteonecrosis of the jaw in patients with bone metastases: a propensity score-matched analysis.
Ikesue H; Doi K; Morimoto M; Hirabatake M; Muroi N; Yamamoto S; Takenobu T; Hashida T
Support Care Cancer; 2022 Mar; 30(3):2341-2348. PubMed ID: 34738163
[TBL] [Abstract][Full Text] [Related]
11. Medication-related osteonecrosis of the jaw: An update on the memorial sloan kettering cancer center experience and the role of premedication dental evaluation in prevention.
Owosho AA; Liang STY; Sax AZ; Wu K; Yom SK; Huryn JM; Estilo CL
Oral Surg Oral Med Oral Pathol Oral Radiol; 2018 May; 125(5):440-445. PubMed ID: 29580668
[TBL] [Abstract][Full Text] [Related]
12. Osteonecrosis of the jaw among patients with cancer treated with denosumab or zoledronic acid: Results of a regulator-mandated cohort postauthorization safety study in Denmark, Norway, and Sweden.
Ehrenstein V; Heide-Jørgensen U; Schiødt M; Akre O; Herlofson BB; Hansen S; Larsson Wexell C; Nørholt SE; Tretli S; Kjellman A; Glennane A; Lowe KA; Sørensen HT
Cancer; 2021 Nov; 127(21):4050-4058. PubMed ID: 34310704
[TBL] [Abstract][Full Text] [Related]
13. Osteonecrosis of the Jaw in Patients Receiving Bone-Targeted Therapies: An Overview--Part I.
Turner B; Drudge-Coates L; Ali S; Pati J; Nargund V; Ali E; Cheng L; Wells P
Urol Nurs; 2016; 36(3):111-6, 154. PubMed ID: 27501591
[TBL] [Abstract][Full Text] [Related]
14. Medication-related osteonecrosis of the jaw: risk factors in patients under biphosphonate versus patients under antiresorptive-antiangiogenic drugs.
Ghidini G; Manfredi M; Giovannacci I; Mergoni G; Sarraj A; Mureddu M; Giunta G; Bonanini M; Meleti M; Vescovi P
Minerva Stomatol; 2017 Aug; 66(4):135-140. PubMed ID: 28497661
[TBL] [Abstract][Full Text] [Related]
15. Bisphosphonates and other bone agents for breast cancer.
Wong MH; Stockler MR; Pavlakis N
Cochrane Database Syst Rev; 2012 Feb; (2):CD003474. PubMed ID: 22336790
[TBL] [Abstract][Full Text] [Related]
16. Medication-Related Osteonecrosis of the Jaws in the Pediatric Population.
Neal TW; Schlieve T
J Oral Maxillofac Surg; 2022 Oct; 80(10):1686-1690. PubMed ID: 35931181
[TBL] [Abstract][Full Text] [Related]
17. Denosumab versus bisphosphonates for the treatment of bone metastases from solid tumors: a systematic review.
Matuoka JY; Kahn JG; Secoli SR
Eur J Health Econ; 2019 Jun; 20(4):487-499. PubMed ID: 30382484
[TBL] [Abstract][Full Text] [Related]
18. A real-world study on the prevalence and risk factors of medication related osteonecrosis of the jaw in cancer patients with bone metastases treated with Denosumab.
Bracchi P; Zecca E; Brunelli C; Miceli R; Tinè G; Maniezzo M; Lo Dico S; Caputo M; Shkodra M; Caraceni AT
Cancer Med; 2023 Sep; 12(17):18317-18326. PubMed ID: 37559413
[TBL] [Abstract][Full Text] [Related]
19. Incidence of osteonecrosis of the jaw by the use of osteoclast inhibitors in patients with bone metastases: a retrospective cohort study.
Chaurand-Lara J; Pacheco-Ruiz L; Trejo-Campos JL; Facio-Umaña JA; Mora-Pérez J
Cir Cir; 2019; 87(4):396-401. PubMed ID: 31264983
[TBL] [Abstract][Full Text] [Related]
20. Denosumab-related osteonecrosis of the jaw: a report of 2 cases and review of the literature.
Chehal H; Nikitakis NG; Islam MN; Goodchild JH; Mordini L; Bhattacharyya I
Gen Dent; 2019; 67(1):42-46. PubMed ID: 30644830
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
